Skip to main content
Erschienen in: Surgery Today 12/2014

01.12.2014 | Original Article

Factors predicting the surgical outcome in patients with T3/4 lung cancer

verfasst von: Hidetaka Uramoto, Hidehiko Shimokawa, Takeshi Hanagiri, Yoshinobu Ichiki, Fumihiro Tanaka

Erschienen in: Surgery Today | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Locally advanced lung cancer, such as T3/4 tumors, is considered to have a significantly worse prognosis than lower-stage disease, and the treatment of these tumors is difficult. Nevertheless, the information regarding the optimal treatment of T3/4 lung cancers after an operation is still limited. This study evaluated the prognostic factors for the postoperative outcome in patients with T3/4 lung cancers.

Methods

The results of the surgical treatments were retrospectively analyzed for 212 patients with pathological T3 and 197 patients with T4 disease.

Results

The global 5-year survival rate was 30.7 % in this series. The 5-year overall survival (OS) rate in patients with T3 disease was 36.1 %, while that in patients with T4 disease was 24.8 %. The prognosis in females, those with N0-1 disease and those who underwent a complete resection was better than that of the other patients in both the T3 and T4 subgroups. The examination of the OS according to a time series showed that the rate was higher in more recent versus less recent years. From the standpoint of pulmonary metastasis (PM), the 5-year OS rates in T4 patients with PM and without PM were 38.6 and 17.4 %, respectively. Multivariate analyses demonstrated that female gender, T3 disease, N0-1 disease and postoperative treatment were significant favorable prognostic predictors for OS.

Conclusions

These findings suggest that surgical resection remains an important treatment option, especially in cases having the aforementioned factors.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Lococo F, Cesario A, Margaritora S, Dall’Armi V, Nachira D, Cusumano G, et al. Induction therapy followed by surgery for T3–T4/N0 non-small cell lung cancer: long-term results. Ann Thorac Surg. 2012;93:1633–40.PubMedCrossRef Lococo F, Cesario A, Margaritora S, Dall’Armi V, Nachira D, Cusumano G, et al. Induction therapy followed by surgery for T3–T4/N0 non-small cell lung cancer: long-term results. Ann Thorac Surg. 2012;93:1633–40.PubMedCrossRef
3.
Zurück zum Zitat Suzuki M, Yoshida S, Moriya Y, Hoshino H, Mizobuchi T, Okamoto T, et al. Surgical outcomes of newly categorized peripheral T3 non-small cell lung cancers: comparisons between chest wall invasion and large tumors (> 7 cm). Interact Cardiovasc Thorac Surg. 2010;11:420–4.PubMedCrossRef Suzuki M, Yoshida S, Moriya Y, Hoshino H, Mizobuchi T, Okamoto T, et al. Surgical outcomes of newly categorized peripheral T3 non-small cell lung cancers: comparisons between chest wall invasion and large tumors (> 7 cm). Interact Cardiovasc Thorac Surg. 2010;11:420–4.PubMedCrossRef
4.
Zurück zum Zitat Endoh H, Yamamoto R, Satoh Y, Kuwano H, Nishizawa N. Risk analysis of pulmonary resection for elderly patients with lung cancer. Surg Today. 2013;43:514–20.PubMedCrossRef Endoh H, Yamamoto R, Satoh Y, Kuwano H, Nishizawa N. Risk analysis of pulmonary resection for elderly patients with lung cancer. Surg Today. 2013;43:514–20.PubMedCrossRef
5.
Zurück zum Zitat Hanagiri T, Shinohara S, Takenaka M, Shimokawa H, Nagata Y, Nakagawa M, et al. Clinical characteristics of resected T3 non-small cell lung cancer characterized by parietal pleural invasion or chest wall invasion. Indian J Surg (in press). Hanagiri T, Shinohara S, Takenaka M, Shimokawa H, Nagata Y, Nakagawa M, et al. Clinical characteristics of resected T3 non-small cell lung cancer characterized by parietal pleural invasion or chest wall invasion. Indian J Surg (in press).
6.
Zurück zum Zitat Doddoli C, D’Journo B, Le Pimpec-Barthes F, Dujon A, Foucault C, Thomas P, et al. Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg. 2005;80:2032–40.PubMedCrossRef Doddoli C, D’Journo B, Le Pimpec-Barthes F, Dujon A, Foucault C, Thomas P, et al. Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg. 2005;80:2032–40.PubMedCrossRef
7.
Zurück zum Zitat Di Perna CA, Wood DE. Surgical management of T3 and T4 lung cancer. Clin Cancer Res. 2005;11:5038s–44s.CrossRef Di Perna CA, Wood DE. Surgical management of T3 and T4 lung cancer. Clin Cancer Res. 2005;11:5038s–44s.CrossRef
8.
Zurück zum Zitat Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007;25:313–8.PubMedCrossRef Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007;25:313–8.PubMedCrossRef
9.
Zurück zum Zitat Yildizeli B, Dartevelle PG, Fadel E, Mussot S, Chapelier A. Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: the benefit is worth the risk. Ann Thorac Surg. 2008;86:1065–75.PubMedCrossRef Yildizeli B, Dartevelle PG, Fadel E, Mussot S, Chapelier A. Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: the benefit is worth the risk. Ann Thorac Surg. 2008;86:1065–75.PubMedCrossRef
10.
Zurück zum Zitat Yang HX, Hou X, Lin P, Rong TH, Yang H, Fu JH. Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer. Ann Thorac Surg. 2009;88:372–8.PubMedCrossRef Yang HX, Hou X, Lin P, Rong TH, Yang H, Fu JH. Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer. Ann Thorac Surg. 2009;88:372–8.PubMedCrossRef
11.
Zurück zum Zitat Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T, Yasumoto K. Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol. 2010;5:1136–42.PubMedCrossRef Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T, Yasumoto K. Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol. 2010;5:1136–42.PubMedCrossRef
12.
Zurück zum Zitat Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH, Kim JH. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol. 2013;8(2):171–8.PubMedCrossRef Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH, Kim JH. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol. 2013;8(2):171–8.PubMedCrossRef
13.
Zurück zum Zitat Farjah F, Flum DR, Ramsey SD, Heagerty PJ, Symons RG, Wood DE. Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol. 2009;4:355–63.PubMedCentralPubMedCrossRef Farjah F, Flum DR, Ramsey SD, Heagerty PJ, Symons RG, Wood DE. Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol. 2009;4:355–63.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Yoshino I, Yoshida S, Miyaoka E, Asamura H, Nomori H, Fujii Y, et al. Japanese Joint Committee of Lung Cancer Registration. Surgical outcome of stage IIIA- cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004. J Thorac Oncol. 2012;7:850–5.PubMedCrossRef Yoshino I, Yoshida S, Miyaoka E, Asamura H, Nomori H, Fujii Y, et al. Japanese Joint Committee of Lung Cancer Registration. Surgical outcome of stage IIIA- cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004. J Thorac Oncol. 2012;7:850–5.PubMedCrossRef
15.
Zurück zum Zitat Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M, et al. Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. Ann Surg Oncol. 2012;19:2685–92.PubMedCentralPubMedCrossRef Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M, et al. Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer. Ann Surg Oncol. 2012;19:2685–92.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Nagai K, Sohara Y, Tsuchiya R, Goya T, Miyaoka E, Japan Lung Cancer Registration Committee. Prognosis of resected non-small cell lung cancer patients with intrapulmonary metastases. J Thorac Oncol. 2007;2:282–6.PubMedCrossRef Nagai K, Sohara Y, Tsuchiya R, Goya T, Miyaoka E, Japan Lung Cancer Registration Committee. Prognosis of resected non-small cell lung cancer patients with intrapulmonary metastases. J Thorac Oncol. 2007;2:282–6.PubMedCrossRef
Metadaten
Titel
Factors predicting the surgical outcome in patients with T3/4 lung cancer
verfasst von
Hidetaka Uramoto
Hidehiko Shimokawa
Takeshi Hanagiri
Yoshinobu Ichiki
Fumihiro Tanaka
Publikationsdatum
01.12.2014
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 12/2014
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-014-0861-0

Weitere Artikel der Ausgabe 12/2014

Surgery Today 12/2014 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.